Beta Bionics Reports Strong Q1 Earnings with Revenue Growth and Margin Expansion
Beta Bionics reported Q1 net sales of $27.6 million, a 57% increase year-over-year, driven by new patient starts and recurring pharmacy users. The company also raised its full-year 2026 revenue outlook and saw a significant expansion in gross margin to 59.5%.
Tickers: $BBNX
Topics: bi-hormonal system earnings FDA warning letter iLet insulin delivery system Mint patch-pump pharmacy channel revenue growth